Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
elicits varying degrees of protective immunity conferred by neutralizing antibodies (nAbs). In …

Abstract Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no
licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal …

Background COVID-19 has caused more than 2.6 billion infections and several million
deaths since its outbreak 2 years ago. We know very little about the long-term cellular …

Major advances have been made in understanding the dynamics of humoral immunity
briefly after the acute coronavirus disease 2019 (COVID-19). However, knowledge …

Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global
public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to …

Adaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dynamics remain largely unknown. The neutralizing antibody (NAb) levels in patients with …

Objectives As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent
need to characterize immune correlates of protection from severe acute respiratory …

The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet
well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody …

Humoral immunity confers protection against COVID-19. The longevity of antibody
responses after receiving an inactivated vaccine in individuals with previous SARS-CoV-2 …

In order to support vaccine development, and to aid convalescent plasma therapy, it would
be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing …